341 related articles for article (PubMed ID: 20061171)
1. Classical maple syrup urine disease and brain development: principles of management and formula design.
Strauss KA; Wardley B; Robinson D; Hendrickson C; Rider NL; Puffenberger EG; Shellmer D; Moser AB; Morton DH
Mol Genet Metab; 2010 Apr; 99(4):333-45. PubMed ID: 20061171
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of maple syrup disease: a study of 36 patients.
Morton DH; Strauss KA; Robinson DL; Puffenberger EG; Kelley RI
Pediatrics; 2002 Jun; 109(6):999-1008. PubMed ID: 12042535
[TBL] [Abstract][Full Text] [Related]
3. Branched-chain α-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes.
Strauss KA; Carson VJ; Soltys K; Young ME; Bowser LE; Puffenberger EG; Brigatti KW; Williams KB; Robinson DL; Hendrickson C; Beiler K; Taylor CM; Haas-Givler B; Chopko S; Hailey J; Muelly ER; Shellmer DA; Radcliff Z; Rodrigues A; Loeven K; Heaps AD; Mazariegos GV; Morton DH
Mol Genet Metab; 2020 Mar; 129(3):193-206. PubMed ID: 31980395
[TBL] [Abstract][Full Text] [Related]
4. Living related versus deceased donor liver transplantation for maple syrup urine disease.
Feier F; Schwartz IV; Benkert AR; Seda Neto J; Miura I; Chapchap P; da Fonseca EA; Vieira S; Zanotelli ML; Pinto e Vairo F; Camelo JS; Margutti AV; Mazariegos GV; Puffenberger EG; Strauss KA
Mol Genet Metab; 2016 Mar; 117(3):336-43. PubMed ID: 26786177
[TBL] [Abstract][Full Text] [Related]
5. Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease.
Zinnanti WJ; Lazovic J; Griffin K; Skvorak KJ; Paul HS; Homanics GE; Bewley MC; Cheng KC; Lanoue KF; Flanagan JM
Brain; 2009 Apr; 132(Pt 4):903-18. PubMed ID: 19293241
[TBL] [Abstract][Full Text] [Related]
6. Successful pregnancy in maple syrup urine disease: a case report and review of the literature.
Grünert SC; Rosenbaum-Fabian S; Schumann A; Schwab KO; Mingirulli N; Spiekerkoetter U
Nutr J; 2018 May; 17(1):51. PubMed ID: 29753318
[TBL] [Abstract][Full Text] [Related]
7. Glucose and alanine metabolism in children with maple syrup urine disease.
Haymond MW; Ben-Galim E; Strobel KE
J Clin Invest; 1978 Aug; 62(2):398-405. PubMed ID: 670400
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of branched-chain amino acid intake in children with maple syrup urine disease and methylmalonic aciduria.
Parsons HG; Carter RJ; Unrath M; Snyder FF
J Inherit Metab Dis; 1990; 13(2):125-36. PubMed ID: 2116544
[TBL] [Abstract][Full Text] [Related]
9. Markers associated with inborn errors of metabolism of branched-chain amino acids and their relevance to upper levels of intake in healthy people: an implication from clinical and molecular investigations on maple syrup urine disease.
Mitsubuchi H; Owada M; Endo F
J Nutr; 2005 Jun; 135(6 Suppl):1565S-70S. PubMed ID: 15930470
[TBL] [Abstract][Full Text] [Related]
10. Total branched-chain amino acids requirement in patients with maple syrup urine disease by use of indicator amino acid oxidation with L-[1-13C]phenylalanine.
Riazi R; Rafii M; Clarke JT; Wykes LJ; Ball RO; Pencharz PB
Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E142-9. PubMed ID: 14970005
[TBL] [Abstract][Full Text] [Related]
11. Congenital Hyperinsulinism and Maple Syrup Urine Disease: A Challenging Combination.
Al Shidhani A; Al Hinai A; Al Thihli K; Al Mandhari H; Al Yaarubi S; Ullah I; Al-Hashmi N; Al Murshedi F
J Clin Res Pediatr Endocrinol; 2023 Aug; 15(3):302-306. PubMed ID: 34738771
[TBL] [Abstract][Full Text] [Related]
12. Maple syrup urine disease: magnetic resonance imaging findings in three patients.
Allahwala A; Ahmed S; Afroze B
J Pak Med Assoc; 2021 Apr; 71(4):1309-1313. PubMed ID: 34125801
[TBL] [Abstract][Full Text] [Related]
13. Acrodermatitis dysmetabolica in an infant with maple syrup urine disease.
Flores K; Chikowski R; Morrell DS
Clin Exp Dermatol; 2016 Aug; 41(6):651-4. PubMed ID: 27334242
[TBL] [Abstract][Full Text] [Related]
14. Brain Branched-Chain Amino Acids in Maple Syrup Urine Disease: Implications for Neurological Disorders.
Xu J; Jakher Y; Ahrens-Nicklas RC
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050626
[TBL] [Abstract][Full Text] [Related]
15. Intravenous branched-chain amino-acid-free solution for the treatment of metabolic decompensation episodes in Spanish pediatric patients with maple syrup urine disease.
Sánchez-Pintos P; Meavilla S; López-Ramos MG; García-Cazorla Á; Couce ML
Front Pediatr; 2022; 10():969741. PubMed ID: 36046474
[TBL] [Abstract][Full Text] [Related]
16. Diurnal changes in plasma amino acids in maple syrup urine disease.
Schwahn B; Wendel U; Schadewaldt P; Falkenberg N; Mönch E
Acta Paediatr; 1998 Dec; 87(12):1245-6. PubMed ID: 9894823
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress in plasma from maple syrup urine disease patients during treatment.
Barschak AG; Sitta A; Deon M; Barden AT; Dutra-Filho CS; Wajner M; Vargas CR
Metab Brain Dis; 2008 Mar; 23(1):71-80. PubMed ID: 18026828
[TBL] [Abstract][Full Text] [Related]
18. Oral enzyme therapy for maple syrup urine disease (MSUD) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primates.
Skvorak K; Liu J; Kruse N; Mehmood R; Das S; Jenne S; Chng C; Lao UL; Duan D; Asfaha J; Du F; Teadt L; Sero A; Ching C; Riggins J; Pope L; Yan P; Mashiana H; Ismaili MHA; McCluskie K; Huisman G; Silverman AP
J Inherit Metab Dis; 2023 Nov; 46(6):1089-1103. PubMed ID: 37494004
[TBL] [Abstract][Full Text] [Related]
19. Acute illness in maple syrup urine disease: dynamics of protein metabolism and implications for management.
Thompson GN; Francis DE; Halliday D
J Pediatr; 1991 Jul; 119(1 Pt 1):35-41. PubMed ID: 2066856
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
